A Phase 3 study revealed that the targeted chemotherapy sacituzumab tirumotecan, developed by Kelun-Biotech and licensed to Merck, reduced tumor progression risk by 65% in lung cancer patients, with potential preliminary survival benefits needing further confirmation. This study marks the first successful use of an antibody-drug conjugate combined with PD-1-targeted immunotherapy in previously untreated advanced non-small cell lung cancer patients.
The most valuable insight for you is the successful Phase 3 results of sacituzumab tirumotecan (sac-TMT), an antibody-drug conjugate developed by Kelun-Biotech and Merck, which cut the risk of tumor progression by 65% in untreated non-small cell lung cancer. This marks a significant advancement in combining targeted chemotherapy with immunotherapy, potentially impacting future therapeutic strategies and investment opportunities in oncology-focused biotech.